Good MorningStocks ended the day lower after the S&P 500 initially reached an intra-day high. Even the tech-heavy NASDAQ finished in the red despite an additional 2% increase in NVIDIA stock. The VIX ended the day higher, as did gold.
One day doesn’t make a pattern, but with earnings season two weeks away, investors could be looking at economic indicators. If that’s the case, they got disappointing news from August home sales, which were down 4.7%.
Their attention will now shift to the final reading on second-quarter GDP, which will be released on Thursday morning. On Friday, investors will get the latest reading of the PCE index.
Investors aren’t expecting any surprises at this time. But as the saying goes, “That’s why they play the games.” Any negative surprises could fuel recession fears and push stocks lower. Featured: Buffett to put 90% of his money in this one stock? (Ad) 
|
Markets | | |
When companies announce their quarterly earnings results, they can often get sucked into the market's price action for that day, especially if other news or economic data come in to trump the importance of the quarterly release for that stock. That is the case today with shares of AutoZone Inc. ... Read the Full Story |
|
From Our Partners | | How to Collect Up To $5,917/mo From Trump's Made In USA Boom
Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America.
But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month.
Don't miss your chance to participate directly in America's industrial comeback. | | Watch Now to Learn How to Get Your First Check in 30 Days |
|
Stocks | | | U.S. stocks rose to another record Thursday as financial markets around the world rallied again.The S&P 500 added 0.4% to set an all-time high for the third time this week and the 42nd time this year. The Dow Jones Industrial Average gained 260 points, or 0.6%, to finish just shy of its record,... Read the Full Story |
|
Stocks | | |
On September 27, 2024, investors will get the latest reading on inflation from the Personal Consumption Expenditures (PCE) index. In August, the reading came in at 2.5%. This means that year-over-year prices were increasing by 2.5%.
It’s no wonder that many consumers, particularly lo... Read the Full Story |
|
From Our Partners | | Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity.
While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | | Watch the Bitcoin Skimming strategy here |
|
Markets | | |
Palantir Technologies Inc. (NYSE: PLTR) began trading as a member of the S&P 500 index on September 23, 2024. Inclusion in the index was a long-time goal of Palantir. It’s also a significant milestone for retail investors who have largely driven the growth of PLTR stock since it went pub... Read the Full Story |
|
Markets | | | The rush for gold just keeps coming.Gold hit another all time high this week. Recent gains for the precious metal are largely credited to ongoing economic uncertainty, geopolitical tensions and strong demand from central banks around the world. If trends continue, analysts have bullish outlooks on t... Read the Full Story |
|
From Our Partners | | The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. | | Click here to see the Tesla shock that could blindside everyone. |
|
Markets | | | Southwest Airlines plans to eliminate about one-third of its flights to Atlanta next year to save money as it comes under pressure from a hedge fund to increase profits and boost the airline’s stock price.The retreat in Atlanta, where Southwest is far smaller than Delta Air Lines, will eliminate mor... Read the Full Story |
|
Markets | | | Southwest Airlines executives have unveiled their vision for turning the carrier into an airline that gives passengers assigned seats, charges them extra for more legroom and offers red-eye flights but bags still fly free Read the Full Story |
|
Markets | | |
A treasury bill is a short-term government debt security offering a high level of security and low risk. When you purchase a treasury bill, you essentially lend money to the government to complete short-term projects with timelines of less than one year. Because these investments are backed by the... Read the Full Story |
|
Markets | | | The executive board of the International Monetary Fund has approved a new $7 billion loan for cash-strapped Pakistan, authorities said Wednesday, more than two months after the two sides said they had reached an agreement. The loan — which Islamabad will receive in installments over 37 months — is a... Read the Full Story |
|
Markets | | |
Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. Yet, with still only a market cap of $2.4 billion, is there still time to get in? I’ll examine recent n... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. | | View Today's Stock Pick |
|
